유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - вирусът на морбили щам edmonston enders' (на живо, хлътване), вируса на паротит jeryl lynn (ниво b) щам (на живо, хлътване), вируса на краснухи Вистар ra 27/3 щам (на живо, отслабена) - rubella; mumps; immunization; measles - Ваксини - М-м-rvaxpro е предназначен за едновременна ваксинация срещу морбили, паротит и краснухи лица 12 месеца и по-големи. За използване на светкавица кори, или за постконтактной ваксинация, или за използване в по-рано непривитым деца над 12 месеца, които влизат в контакт с възприемчиви за бременни, а лица, които могат да бъдат изложени паротит и краснухи.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

mylan ireland limited - диметил фумарат - Множествена Склероза, Рецидивно-Ремиттирующее - Имуносупресори - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - Имуносупресори - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. Псориатичен arthritiscosentyx, самостоятелно или в комбинация с метотрексат (mtx), се предписва за лечение на активен псориатичен артрит при възрастни пациенти, когато в отговор на предишно заболяване дорабатывая анти-ревматични лекарства (dmards) терапия е неадекватна.. Аксиальный спондилит (axspa)анкилозиращ спондилит (като, радиографические аксиален спондилит)cosentyx е показан за лечение на активна анкилозирующего спондилита при възрастни, които недостатъчно са отговорили на стандартна терапия. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, валсартан - Сърдечна недостатъчност - Антагонисти на ангиотензин ii, други комбинации, агенти, действащи върху ренин-ангиотензиновую система - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

novartis europharm limited - вилдаглиптин, метформин хидрохлорид - Захарен диабет тип 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

novartis europharm limited - вилдаглиптин - Захарен диабет тип 2 - Лекарства, използвани при диабет - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

novartis europharm limited - вилдаглиптин, метформин хидрохлорид - Захарен диабет тип 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 и 5. 1 за наличните данни за различни комбинации).

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

novartis europharm limited - вилдаглиптин - Захарен диабет тип 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 и 5. 1 за наличните данни за различни комбинации).

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, валсартан - Сърдечна недостатъчност - Агенти, действащи върху системата ренин-ангиотензин - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

novartis europharm limited  - вилдаглиптин, метформин хидрохлорид - Захарен диабет тип 2 - Лекарства, използвани при диабет - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.